Home > Publications database > Immunotherapeutic Strategies for the Treatment of Glioblastoma: Current Challenges and Future Perspectives. > print

001     289470
005     20241106102215.0
024 7 _ |a 10.3390/cancers16071276
|2 doi
024 7 _ |a pmid:38610954
|2 pmid
024 7 _ |a pmc:PMC11010873
|2 pmc
024 7 _ |a altmetric:162413876
|2 altmetric
037 _ _ |a DKFZ-2024-00792
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Salvato, Ilaria
|0 0000-0002-9659-2703
|b 0
245 _ _ |a Immunotherapeutic Strategies for the Treatment of Glioblastoma: Current Challenges and Future Perspectives.
260 _ _ |a Basel
|c 2024
|b MDPI
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1713268812_20784
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #LA:D490#
520 _ _ |a Despite decades of research and the best up-to-date treatments, grade 4 Glioblastoma (GBM) remains uniformly fatal with a patient median overall survival of less than 2 years. Recent advances in immunotherapy have reignited interest in utilizing immunological approaches to fight cancer. However, current immunotherapies have so far not met the anticipated expectations, achieving modest results in their journey from bench to bedside for the treatment of GBM. Understanding the intrinsic features of GBM is of crucial importance for the development of effective antitumoral strategies to improve patient life expectancy and conditions. In this review, we provide a comprehensive overview of the distinctive characteristics of GBM that significantly influence current conventional therapies and immune-based approaches. Moreover, we present an overview of the immunotherapeutic strategies currently undergoing clinical evaluation for GBM treatment, with a specific emphasis on those advancing to phase 3 clinical studies. These encompass immune checkpoint inhibitors, adoptive T cell therapies, vaccination strategies (i.e., RNA-, DNA-, and peptide-based vaccines), and virus-based approaches. Finally, we explore novel innovative strategies and future prospects in the field of immunotherapy for GBM.
536 _ _ |a 314 - Immunologie und Krebs (POF4-314)
|0 G:(DE-HGF)POF4-314
|c POF4-314
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a CAR-T cell therapy
|2 Other
650 _ 7 |a DNA/RNA vaccines
|2 Other
650 _ 7 |a GBM
|2 Other
650 _ 7 |a GBM immunosuppressive tumor microenvironment
|2 Other
650 _ 7 |a adoptive cell therapy
|2 Other
650 _ 7 |a immune checkpoint therapy
|2 Other
650 _ 7 |a immunotherapy
|2 Other
650 _ 7 |a oncolytic virotherapy
|2 Other
650 _ 7 |a vaccination therapy
|2 Other
700 1 _ |a Marchini, Antonio
|0 P:(DE-He78)2c1968abb9781c0328997892355fa74c
|b 1
|e Last author
|u dkfz
773 _ _ |a 10.3390/cancers16071276
|g Vol. 16, no. 7, p. 1276 -
|0 PERI:(DE-600)2527080-1
|n 7
|p 1276
|t Cancers
|v 16
|y 2024
|x 2072-6694
856 4 _ |u https://inrepo02.dkfz.de/record/289470/files/cancers-16-01276-v3.pdf
856 4 _ |u https://inrepo02.dkfz.de/record/289470/files/cancers-16-01276-v3.pdf?subformat=pdfa
|x pdfa
909 C O |o oai:inrepo02.dkfz.de:289470
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)2c1968abb9781c0328997892355fa74c
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-314
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Immunologie und Krebs
|x 0
914 1 _ |y 2024
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CANCERS : 2022
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-07-31T16:07:06Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-07-31T16:07:06Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2023-07-31T16:07:06Z
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2023-07-31T16:07:06Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-10-26
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-26
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-10-26
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b CANCERS : 2022
|d 2023-10-26
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2023-10-26
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2023-10-26
920 2 _ |0 I:(DE-He78)D490-20160331
|k D490
|l KKE Virotherapie
|x 0
920 1 _ |0 I:(DE-He78)F230-20160331
|k F230
|l KKE Virotherapie
|x 0
920 1 _ |0 I:(DE-He78)D490-20160331
|k D490
|l KKE Virotherapie
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)F230-20160331
980 _ _ |a I:(DE-He78)D490-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21